Skip to main content
SpringerLink
Log in

The Role of Photodynamic Therapy in Retinal Vascular Disease

  • Chapter
Retinal Vascular Disease

Abstract

Photodynamic therapy (PDT) with verteporfin has significantly improved functional outcome in the treatment of choroidal neovascularization (CNV) in various clinical disorders [86]. While CNV due to age-related macular degeneration [4, 53, 76–80, 84] and pathologic myopia [83, 85] was the primary focus, several studies showed that the treatment effects of PDT were not only restricted to these two underlying disorders. Recently, several clinical studies observed PDT as a treatment modality of CNV due to ocular histoplasmosis syndrome [52, 55, 68], choroiditis [71, 89], angioid streaks [31, 37, 68], Stargardt’s disease [81], symptomatic choroidal hemangioma [30, 61, 82] and other causes [15, 72]. While PDT has become an established treatment modality for various choroidal disorders, its role in the treatment of retinal diseases remains to be determined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aaberg TM Jr, Aaberg TMSr, Martin DF, Gilman JP, Myles R (2006) Three cases of large retinal capillary hemangioma treated with verteporfin and photodynamic therapy. Arch Ophthalmol 123:328–332

    Article  Google Scholar 

  2. Allison BA, Waterfield E, Richter AM, Levy JG (1991) The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 54:709–715

    PubMed  CAS  Google Scholar 

  3. Anastassiou G, Bornfeld N, Schüler AO, Schilling H, Weber S, Flühs D, Jurklies B, Sauerwein W (2006) Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina. Br J Ophthalmol 90:447–450

    Article  PubMed  CAS  Google Scholar 

  4. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, Lim JI, Miller JW, Potter MJ, Reaves A, Rosenfeld PJ, Sickenberg M, Slakter JS, Soubrane G, Strong HA, Stur M, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group (2004) Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP repor tNo. 3. Am J Ophthalmol 137:683–696

    Article  PubMed  CAS  Google Scholar 

  5. Atebara NH (2002) Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol 134:788–790

    Article  PubMed  Google Scholar 

  6. Bakri SJ, Sears JE, Singh AD (2005) Transient closure of a retinal capillary hemangioma with verteporfin. Retina 25:1103–1104

    Article  PubMed  Google Scholar 

  7. Barbazetto IA, Smith RT (2003) Vasoproliferative tumor of the retina treated with PDT. Retina 23:565–567

    Article  Google Scholar 

  8. Berger JW (1999) Macular laser tissue interactions: implications for treatment and prophylaxis, Chapter 14. In: Berger JW, Fine SL, Maguire MG (eds) Age-related macular degeneration. Mosby, St. Louis, pp 249–261

    Google Scholar 

  9. Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E (2006) Photodynamic therapy for vasoproliferative retinal tumors. Retina 26:404–409

    Article  PubMed  Google Scholar 

  10. Bloom SM, Brucker AJ (1997) Principles of photocoagulation. In: Laser surgery of the posterior eye segment, Chapter 1. Lippincott-Raven, Philadelphia, pp 3–36

    Google Scholar 

  11. De Lahitte GD, Cohen SY, Gaudric A (2004) Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal teleangiectasis without subretinal neovascularization. Am J Ophthalmol 138:892–894

    Article  PubMed  Google Scholar 

  12. De Vree WJ, Essers MC, Koster JF, Sluiter W (1997) Role of interleukin 1 and granulocyte colony stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res 57:2555–2558

    PubMed  Google Scholar 

  13. Dougherty TJ (1984) Photodynamic therapy of malignant tumors. Crit Rev Oncol Hematol 2:83–116

    Article  PubMed  CAS  Google Scholar 

  14. Dougherty TJ, Gomer CJ, Henderson B, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905

    Article  PubMed  CAS  Google Scholar 

  15. Ergun E, Tittl M, Stur M (2004) Photodynamic therapy with Verteporfin in subfoveal choroidal neovascularization to central serous chorioretinopathy. Arch Ophthalmol 122:37–41

    Article  PubMed  CAS  Google Scholar 

  16. Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI (1990) Effect of photodynamic therapy on tumor necrosis production by murine macrophages. J Natl Cancer Inst 82:34–39

    Article  PubMed  CAS  Google Scholar 

  17. Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14:323–328

    PubMed  CAS  Google Scholar 

  18. Gass JD, Blodi B (1993) Idiopathic juxtafoveolar retinal teleangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536–1546

    PubMed  CAS  Google Scholar 

  19. Ghazi NA, Jabbour NM, De La Cruz ZC, Green WR (2001) Clinicopathologic studies of age-relatedmacular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 21:478–486

    Article  PubMed  CAS  Google Scholar 

  20. Gibson SL, Murant RS, Hilf R (1988) Photosensitizing effects of hematoporphyrin derivative and Photofrin II on the plasma membrane enzymes 5′nucleotidase, Na+ K+ ATPase, and Mg2+ ATPase in R3230AC rat mammary adenocarcinomas. Cancer Res 48:3360–3366

    PubMed  CAS  Google Scholar 

  21. Gomer CJ (1989) Photodynamic therapy in the treatment of malignancies. Semin Hematol 26:24–34

    Google Scholar 

  22. Haimovici R, Kramer M, Miller JW, et al. (1997) Localization of the lipoprotein delivered benzoporphyrin derivative in the rabbit. Curr Eye Res 16:83–90

    Article  PubMed  CAS  Google Scholar 

  23. Heimann H, Bornfeld N, Vij O, Coupland SE, Bechrakis NE, Kellner U, Foerster MH (2000) Vasoproliferative tumors of the retina. Br J Ophthalmol 84:1162–1169

    Article  PubMed  CAS  Google Scholar 

  24. Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55:145–157

    PubMed  CAS  Google Scholar 

  25. Husain D, Miller JW, Michaud N, Connolly E, Flotte T, Gragoudas E (1996) Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 114:978–986

    PubMed  CAS  Google Scholar 

  26. Husain D, Kramer M, Kenny AG, Michaud N, Flotte T, Gragoudas E, Miller JW (1999) Effects of photodynamic therapy on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40:2322–2331

    PubMed  CAS  Google Scholar 

  27. Hussain N, Das T, Sumasri K, Ram LS (2005) Bilateral sequential photodynamic therapy for subretinal neovascularization with type 2A parafoveal teleangiectasis. Am J Ophthalmol 140:333–335

    Article  PubMed  Google Scholar 

  28. Johnson MW, Flynn HW, Gass JDM (1992) Pars plana vitrectomy and direct diathermy for complications of multiple retinal angiomas. Ophthalmic Surg 23:47–50

    PubMed  CAS  Google Scholar 

  29. Jori G (1990) Factors controlling the selectivity and efficiency of tumor damage in photodynamic therapy. Lasers Med Sci 5:115–120

    Article  Google Scholar 

  30. Jurklies B, Anastassiou G, Ortmans S, Schüler A, Schilling H, Schmidt-Erfurth U, Bornfeld N (2003) Photodynamic therapy using Verteporfin in circumscribed choroidal hemangioma. Br J Ophthalmol 87:84–89

    Article  PubMed  CAS  Google Scholar 

  31. Jurklies B, Bornfeld N, Schilling H (2006) Photodynamic therapy using Verteporfin for choroidal neovascularization associated with angioid streaks-long-term effects. Ophthalmic Res 38:209–217

    Article  PubMed  CAS  Google Scholar 

  32. Korbelik M (1996) Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 14:329–334

    PubMed  CAS  Google Scholar 

  33. Korbelik M, Krosl G (1994) Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol 60:497–502

    PubMed  CAS  Google Scholar 

  34. Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte T, Gragoudas E (1996) Liposomal benzoporphyrin derivative Verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438

    PubMed  CAS  Google Scholar 

  35. Kreusel KM, Bornfeld N, Lommatzsch A, et al. (1998) Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology 105:1386–1392

    Article  PubMed  CAS  Google Scholar 

  36. McDonald HR (2003) Diagnostic and therapeutic challenges. Juxtapapillary retinal capillary hemangioma. Retina 23:86–91

    Article  PubMed  Google Scholar 

  37. Menchini U, Visgili G, Introini U, Bandello F, Ambesi-Impiombato M, Pece A, Parodi MB, Giacomelli G, Capobianco B, Varano M, Brancato R (2004) Outcome of choroidal neovascularization in angioid streaks after photodynamic therapy. Retina 24:763–771

    Article  PubMed  Google Scholar 

  38. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte T, Haimovici R, Gragoudas E (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 113:810–818

    PubMed  CAS  Google Scholar 

  39. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras C, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane A-M, Birngruber R, van den Berg H, Strong A, Manjuris U, Todd G, Fsadni M, Bressler NM, Gragoudas E (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161–1173

    PubMed  CAS  Google Scholar 

  40. Moan J, Christensen T (1981) Cellular uptake and photodynamic effects of hematoporphyrin. Photochem Photobiol 2:291–299

    CAS  Google Scholar 

  41. Moan J, McGhie J, Jacobsen PB (1983) Photodynamic effects of cells in vitro exposed to hematoporphyrin derivative in light. Photochem Photobiol 37:599–604

    PubMed  CAS  Google Scholar 

  42. Moan J, Peng Q, Evensen JF, Berg K, Western A, Rimington C (1987) Photosensitizing efficiencies, tumor and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol 46:713–721

    PubMed  CAS  Google Scholar 

  43. Moore AT, Maher ER, Rosen P, et al. (1991) Ophthalmological screening for von Hippel Lindau disease. Eye 5:723–728

    PubMed  Google Scholar 

  44. Obochi MO, Ratkay LG, Levy JG (1997) Prolonged skin allograft survival after photodynamic therapy associated with modification of donor skin antigenicity. Transplantation 63:810–817

    Article  PubMed  CAS  Google Scholar 

  45. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females (2004). Am J Ophthalmol 138:803–808

    Article  PubMed  Google Scholar 

  46. Potter MJ, Szabo SM, Sarraf D, Michels R, Schmidt-Erfurth U (2006) Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar teleangiectasis. Can J Ophthalmol 41:034–37

    Google Scholar 

  47. Reinke MH, Canakis C, Husain D, et al. (1999) Verteporfin photodynamic therapy retreatment of normal retina and choroids in the cynomolgus monkey. Ophthalmology 106:1915–1923

    Article  PubMed  CAS  Google Scholar 

  48. Richter AM, Kelly B, Chow J, et al. (1987) Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst 79:1327–1332

    PubMed  CAS  Google Scholar 

  49. Richter AM, Cerruti-Sola S, Sternberg ED, Dolphin D, Levy JG (1990) Biodistribution of tritiated benzoporphyrine derivative (3H-BPD-MA) a new potent photosensitizer in normal and tumor bearing mice. J Photochem Photobiol 53:231–244

    Google Scholar 

  50. Richter AM, Waterfield E, Jain AK, Allison B, Sternberg ED, Dolphin D, Levy JG (1991) Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumor model. Br J Cancer 63:87–93

    PubMed  CAS  Google Scholar 

  51. Rodriguez-Coleman H, Spaide R, Yanuzzi L (2002) Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina 22:228–232

    Article  PubMed  Google Scholar 

  52. Rosenfeld PJ, Saperstein DA, Bressler NM, Reaves TA, Sickenberg M, Rosa RH, Sternberg P, Aaberg TM Sr, Aaberg TM Jr, for the Verteporfin in Ocular Histoplasmosis Study Group (2004) Photodynamic therapy with Verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study. Ophthalmology 111:1725–1733

    Article  PubMed  Google Scholar 

  53. Rubin GS, Bressler N, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No. 4. Retina 22:536–544

    Article  PubMed  Google Scholar 

  54. Ryan SJ (1982) Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol 100:1804–1809

    PubMed  CAS  Google Scholar 

  55. Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH, Sickenberg M, Sternberg P, Aaberg TM Sr, Aaberg TM Jr, Reaves TA, for the Verteporfin in Ocular Histoplasmosis (VOH) Study group (2002) Ophthalmology 109:1499–1505

    Article  PubMed  Google Scholar 

  56. Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, Laqua H, Michels S, Schmidt-Erfurth U (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757

    PubMed  Google Scholar 

  57. Schmidt-Erfurth U, Bauman W, Gragoudas E (1994a) Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101:89–99

    PubMed  CAS  Google Scholar 

  58. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R (1994b) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101:1953–1961

    PubMed  CAS  Google Scholar 

  59. Schmidt-Erfurth U, Diddens H, Birngruber R, Hasan T (1997) Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Ophthalmol 75:54–61

    CAS  Google Scholar 

  60. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 117:1177–1187

    PubMed  CAS  Google Scholar 

  61. Schmidt-Erfurth U, Michels S, Kusserow C, Jurklies B, Augustin A (2002a) Photodynamic therapy for symptomatic choroidal hemangioma: Visual and anatomic results. Ophthalmology 109:2284–2294

    Article  PubMed  Google Scholar 

  62. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehardt U, Viestenz A, Naumann GOH (2002b) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835–844

    PubMed  Google Scholar 

  63. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H (2002c) Photodynamic effects on choroidal neovascularization and physiological choroids. Invest Ophthalmol Vis Sci 43:830–841

    PubMed  Google Scholar 

  64. Schmidt-Erfurth U, Kusserow C, Barabazetto IA, Laqua H (2002d) Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 109:1256–1266

    Article  PubMed  Google Scholar 

  65. Shanmugam MP, Agarwal M (2005) RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal teleangiectasis. Indian J Ophthalmol 53:61–63

    Article  PubMed  Google Scholar 

  66. Shields JA (1993) Response of retinal capillary hemangioma to cryotherapy. Arch Ophthalmol 111:551

    PubMed  CAS  Google Scholar 

  67. Shields JA, Shields CL (1999) Vascular tumors of the retina and optic disc. In: Shields JA, Shields CL (eds) Atlas of intraocular tumors, Chapter 17. Lippincott Williams and Wilkins, Philadelphia, pp 243–267

    Google Scholar 

  68. Sickenberg M, Schmidt-Erfurth U, Miller JW Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM (2000) A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 118:327–336

    PubMed  CAS  Google Scholar 

  69. Singh AD, Nouri M, Shields CL, Shields JA, Perez N (2002) Treatment of retinal capillary hemangioma. Ophthalmology 109:1799–1806

    Article  PubMed  Google Scholar 

  70. Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal teleangiectasis. Am J Ophthalmol 137:812–819

    Article  PubMed  CAS  Google Scholar 

  71. Spaide RF, Freund KB, Slakter J, Sorenson J, Yanuzzi LA, Fisher Y (2002a) Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22:545–549

    Article  PubMed  Google Scholar 

  72. Spaide RE, Donsoff I, Lam DL, Yanuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002b) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529–535

    Article  PubMed  Google Scholar 

  73. Steinert RF, Puliafito CA (1985) The neodymium:YAG laser in ophthalmology: principles and clinical practice of photodisruption. Saunders, Philadelphia

    Google Scholar 

  74. Szabo A, Gehl Z, Seres A (2005) Photodynamic (verteporfin) therapy for retinal capillary hemangioma, with monitoring of feeder and draining blood vessel diameters. Acta Ophthalmol Scan 83:512–513

    Article  Google Scholar 

  75. Thomas JP, Girotti AW (1989) Role of lipid peroxidation in hematoporphyrin derivative-sensitized photokilling of tumor cells: protective effects of glutathione peroxidase. Cancer Res 49:1682–1686

    PubMed  CAS  Google Scholar 

  76. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  77. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119:198–207

    Google Scholar 

  78. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002a) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report 3. Arch Ophthalmol 120:1443–1454

    Google Scholar 

  79. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002b) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: three-year results of an open-label extension of 2 randomized clinical trials-TAP report 5. Arch Ophthalmol 120:1307–1314

    Google Scholar 

  80. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Groups (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report 1 (2003). Am J Ophthalmol 136:407–418

    Article  CAS  Google Scholar 

  81. Valmaggia C, Niederberger H, Helbig H (2002) Photodynamic therapy for choroidal neovascularization in fundus flavimaculatus. Retina 22:111–113

    Article  PubMed  Google Scholar 

  82. Verbraak FD, Schlingemann RO, Keunen JE, de Smet MD (2003) Longstanding symptomatic choroidal hemangioma managed with limited PDT as initial or salvage therapy. Graefes Arch Clin Exp Ophthalmol 241:891–898

    Article  PubMed  CAS  Google Scholar 

  83. Verteporfin in Photodynamic Therapy Study Group (2001a) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with Verteporfin. 1-year results of a randomized clinical trial-VIP report No. 1. Ophthalmology 108:841–852

    Article  Google Scholar 

  84. Verteporfin in Photodynamic Therapy Study Group (2001b) Verteporfin therapy of subfoveal choroidal neovascularization in age-relatedmacular degeneration: Two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560

    Article  Google Scholar 

  85. Verteporfin in Photodynamic Therapy Study Group (2003) Verteporfin of subfoveal choroidal neovascularization in pathologic myopia. 2 year results of a randomized clinical trial-VIP report No. 3. Ophthalmology 110:667–673

    Article  Google Scholar 

  86. Verteporfin Roundtable Participants (2005) Guidelines for using Verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes:Update. Retina 25:119–134

    Article  Google Scholar 

  87. Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin therapy of subfoveally minimally classic choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 123:448–457

    Article  Google Scholar 

  88. Volden G, Christensen T, Moan J (1981) Photodynamic membrane damage of hematoporphyrin derivative treated NHIK 3025 cells in vitro. Photobiochem Photobiophy 3:105–111

    CAS  Google Scholar 

  89. Wachtlin J, Heimann H, Behme T, Foerster MH (2003a) Long-term results after photodynamic therapy with choroidal neovascularization secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 241:899–906

    Article  PubMed  CAS  Google Scholar 

  90. Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH (2003b) Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 241:518–521

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Vitreoretinal Surgery, University of Essen, Hufelandstrasse 55, 45122, Essen, Germany

    Bernhard Jurklies MD & Norbert Bornfeld MD

Authors
  1. Bernhard Jurklies MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norbert Bornfeld MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University of Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Antonia M. Joussen MD, PhD (Professor of Ophthalmology) (Professor of Ophthalmology)

  2. Department of Ophthalmology, Penn State College of Medicine, 500 University, Drive Box 850, Hershey, PA, 17033, USA

    Thomas W. Gardner MD, MS (Professor of Ophthalmology) (Professor of Ophthalmology)

  3. Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Joseph-Stelzmann-Straße 9, 50931, Cologne, Germany

    Bernd Kirchhof MD (Professor of Ophthalmology) (Professor of Ophthalmology)

  4. Doheny Eye Institute, University of Southern California, 1450 San Pablo Street, Los Angeles, CA, 90033, USA

    Stephen J. Ryan MD (Professor of Ophthalmology) (Professor of Ophthalmology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jurklies, B., Bornfeld, N. (2007). The Role of Photodynamic Therapy in Retinal Vascular Disease. In: Joussen, A.M., Gardner, T.W., Kirchhof, B., Ryan, S.J. (eds) Retinal Vascular Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29542-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-29542-6_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-29541-9

  • Online ISBN: 978-3-540-29542-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation